SS
ARQT icon

Sunbelt Securities’s Arcutis Biotherapeutics ARQT Stock Holding History

Sunbelt Securities’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$518 Hold
22
– – ﹤0.01% 2283
2025
Q4 		$639 Hold
22
– – ﹤0.01% 2179
2025
Q3 		$415 Buy
+22
New +$347 ﹤0.01% 2270

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sunbelt Securities's ARQT Position: Q1 2026 in Review

Sunbelt Securities held its Arcutis Biotherapeutics (ARQT) position steady in Q1 2026 at 22 shares worth $518. The position accounts for ﹤0.01% of the portfolio, ranked #2283.

Sunbelt Securities first reported a position in ARQT in Q3 2025 and has held it in 3 quarters since. The position peaked at $639 in Q4 2025. 269 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

  • Sunbelt Securities held 22 shares of Arcutis Biotherapeutics worth $518 as of Q1 2026.
  • Sunbelt Securities left its Arcutis Biotherapeutics share count unchanged in Q1 2026.
  • Arcutis Biotherapeutics made up ﹤0.01% of Sunbelt Securities's portfolio in Q1 2026, its #2283 holding.
  • Sunbelt Securities first reported a position in Arcutis Biotherapeutics in Q3 2025 and has held it in 3 quarters since.
  • Sunbelt Securities's Arcutis Biotherapeutics position peaked at $639 in Q4 2025.
  • 269 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on Sunbelt Securities's 13F filing for Q1 2026, filed 18 May 2026.